Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in France
- Registration Number
- NCT00679640
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to describe the way candesartan is used in heart failure treatment in France (treatment initiation and monitoring), treatment stops occurrence and reasons for and patients clinical evolution
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 450
Inclusion Criteria
- outpatients to whom candesartan has been initiated for less than 30 days or during the consultation to treat heart failure
Exclusion Criteria
- patients included in a clinical trial the last 30 days before consultation
- patients unable to answer the questions for linguistic or cognitive reasons
- patients who will be difficult to follow during the one year study
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description 1 Candesartan Outpatients to whom candesartan has been initiated for less than 30 days or during the consultation to treat heart failure
- Primary Outcome Measures
Name Time Method Profile of patients treated with candesartan for heart failure At inclusion
- Secondary Outcome Measures
Name Time Method Percentage of patients taking correctly its treatment : indication, contraindication, drug titration, treatment monitoring 6 and 12 months after Percentage of patients stopping its treatment and reasons why 12 months after Percentage of hospitalisations due to heart failure and cardiovascular deaths 12 months after
Trial Locations
- Locations (1)
Research Site
🇫🇷Maisons Laffitte, Yvelines, France